Clinical Trial Update: COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID) [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for COVID-19 convalescent plasma in symptomatic COVID-19 patients (FALP-COVID), spanning Phase 2 and Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• COVID-19 Infection

Drugs mentioned

• Convalescent Plasma (convalescent plasma)

Snippet

Sponsor: Fundacion Arturo Lopez Perez | Conditions: COVID-19 Infection, Cancer Patients | Phase 2, Phase 3 | Status: UNKNOWN